This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by McGee, B.
Right arrow Articles by Peloquin, C. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGee, B.
Right arrow Articles by Peloquin, C. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2009, p. 3981-3984, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.01378-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis{triangledown}

Bryan McGee,1,2 Reynaldo Dietze,3 David Jamil Hadad,3 Lucilia Pereira Dutra Molino,3 Ethel Leonor Noia Maciel,3 W. Henry Boom,4 Moises Palaci,3 John L. Johnson,4 and Charles A. Peloquin1,2*

Infectious Disease Pharmacokinetics Laboratory, National Jewish Health, Denver, Colorado,1 School of Medicine, University of Colorado, Denver, Colorado,2 Núcleo de Doenças Infecciosas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo (UFES), Vitória, Brazil,3 Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio4

Received 14 October 2008/ Returned for modification 8 January 2009/ Accepted 23 June 2009

Nineteen adults with pulmonary tuberculosis received linezolid (600 mg) once or twice daily in an early bactericidal activity trial. A one-compartment population model produced median values for the absorption rate constant, volume of distribution, and elimination rate constant of 1.5 h–1, 29.6 liters, and 0.25 h–1 (once daily) and 2.7 h–1, 32.1 liters, and 0.15 h–1 (twice daily). Linezolid administered twice daily produced higher values for free drug area under the concentration-time curve (AUC)/MIC and time above MIC. Both regimens achieved free AUC/MIC ratios > 100. Median times above the MIC for free drug were 100% (twice daily) and 63% (once daily).

* Corresponding author. Present address: College of Pharmacy, University of Florida, Gainesville, FL. Phone: (352) 273-6266. Fax: (352) 273-6804. E-mail: peloquin{at}cop.ufl.edu

{triangledown} Published ahead of print on 29 June 2009.

Antimicrobial Agents and Chemotherapy, September 2009, p. 3981-3984, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.01378-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»